NEW YORK (GenomeWeb) – DiaCarta and MIODx today said they plan to codevelop a diagnostic test to predict immunotherapy response based on MIODx's immune sequencing technology, ClonoMap.

The test will be developed and validated at DiaCarta's CLIA-certified laboratories in the San Francisco Bay Area and Nanjing, China. MIODx is an early-stage immunogenomics company based in San Jose, California, developing a T-cell receptor and B-cell receptor sequencing platform.

Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.